Characterisation of various intravenous immunoglobulin preparations.
Five commercially available immunoglobulin preparations are characterised with regard to molecular weight distribution, immunoglobulin subclass distribution and antibody content. Preparations processed utilising enzymic or chemical modification demonstrate considerable variance of molecular weight species and subclass distribution when compared to native preparations. Similarly, cytomegalovirus and anti-streptolysin O antibody content is dramatically reduced in the modified preparations. Possible reasons for the differences are discussed. In-process inactivation of Human Immunodeficiency Virus is reviewed with regard to one of the native preparations.
Lundblad
J L
JL
Research & Development, Quality Assurance, Cutter Laboratories, Miles Pharmaceutical, Berkeley, California 94701.
Londeree
N
N
Mitra
G
G
D000914:Antibodies, Viral / Q000032:analysis; D000989:Antistreptolysin / Q000032:analysis; D003587:Cytomegalovirus / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000032:analysis* / Q000145:classification / Q000276:immunology; D016756:Immunoglobulins, Intravenous; D007262:Infusions, Intravenous; D008459:Measles virus / Q000276:immunology; D008970:Molecular Weight; D012412:Rubella virus / Q000276:immunology
D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; C040901:rubella antibodies; D000989:Antistreptolysin